JAKARTA – PT Medikaloka Hermina Tbk. (HEAL), a prominent player in Indonesia’s healthcare sector, recently experienced a massive non-regular transaction in the negotiated market of the Indonesia Stock Exchange (IDX). This significant event, which transpired on Friday, September 12, 2025, involved a substantial capital movement, drawing considerable attention from investors and market observers.
The monumental transaction recorded for HEAL shares reached an impressive value of Rp2,410,973,465,000 (Rp2.41 trillion). This colossal figure underscores the scale of activity within the negotiated market. Furthermore, the IDX trading statistics revealed that this non-regular trade encompassed a staggering volume of 1,303,228,900 shares, executed across 27 distinct trading frequencies, indicating concentrated interest in the healthcare provider’s stock.
In the broader market context, HEAL stock concluded the trading day on Friday, September 12, 2025, with a modest gain, edging up 0.87% to close at Rp1,730 per share. This upward movement contributes to a robust year-to-date performance for 2025, with Medikaloka Hermina shares having appreciated by 6.13% from their closing price of Rp1,630 at the end of 2024, signaling positive investor sentiment.
This major transaction coincides with a pivotal development for the issuer, as Medikaloka Hermina has officially addressed the entry of the influential Djarum Group. Through its investment arm, PT Dwimuria Investama Andalan, the Djarum Group has become a significant institutional shareholder in the company, marking a strategic alliance set to reshape HEAL’s future trajectory.
Yulisar Khiat, Deputy Director of Medikaloka Hermina, elaborated on this strategic partnership, emphasizing that the Djarum Group’s involvement unlocks substantial opportunities for collaboration. Specifically, this alliance is expected to bolster and enhance the healthcare services provided by HEAL. Looking ahead, Khiat affirmed the company’s commitment to synergizing with all its shareholders, with a particular focus on prioritizing healthcare services for the vast workforce under the Djarum Group’s umbrella. She projected that approximately 300,000 Djarum Group employees would receive priority care from Hermina hospitals.
Crucially, this momentum is anticipated to significantly aid Medikaloka Hermina in strengthening its brand image as a premier hospital for executive patients. By catering to the specific needs of this segment, HEAL aims to transcend its current market reach. This strategy is designed to not only serve the middle-class demographic but also to expand its market share substantially among upper-class patients, solidifying its position in the premium healthcare segment.
“This is what we will enhance, as many of their [Djarum Group’s] companies cater to the middle to upper classes. This also reinforces our conviction to improve services for executive patients, ensuring that even upper-class patients can receive treatment at Hermina,” Khiat stated during a public exposure held on Wednesday, September 10, 2025, underscoring the company’s strategic vision for elevated patient care and market expansion.
Summary
PT Medikaloka Hermina Tbk. (HEAL) recently experienced a massive non-regular transaction on the Indonesia Stock Exchange (IDX) on September 12, 2025, with shares valued at Rp2.41 trillion for 1.3 billion shares. This significant event occurred as the Djarum Group, through its investment arm PT Dwimuria Investama Andalan, became a major institutional shareholder. HEAL’s stock closed with a modest gain that day, contributing to a 6.13% year-to-date appreciation.
This strategic alliance with the Djarum Group is expected to unlock substantial opportunities, enhancing HEAL’s healthcare services. Hermina will prioritize care for approximately 300,000 Djarum Group employees. The partnership also aims to strengthen Hermina’s brand image as a premier hospital for executive patients, expanding its market share to include upper-class patients.